Long-acting glucagon-like peptide-2 analogs, methods of making and uses
By modifying the structure of GLP-2 analogs and preparing them using solid-phase synthesis, the problem of the short half-life of natural GLP-2 has been solved, resulting in a longer half-life and higher bioactivity, which is suitable for the treatment of gastrointestinal diseases and has good clinical application potential.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SUZHOU QINGRUI BIOTECHNOLOGY CO LTD
- Filing Date
- 2026-01-16
- Publication Date
- 2026-07-17
AI Technical Summary
The short half-life of natural GLP-2 necessitates frequent injections, affecting patient compliance. Existing analogues such as Teduglutide and Apraglutide have short half-lives and low in vitro potency, requiring high doses.
A GLP-2 analogue was designed to increase stability and half-life through structural modification. It was prepared by solid-phase synthesis, and specific substituents were introduced to prolong the half-life and retain biological activity. The specific structure is HGDGSFSDE(NIe)(D-Phe)TILDLX17AARDFIX24WLIQTKITD-XX1-R1. The selection of XX1 and R1 was optimized to improve chemical stability.
GLP-2 analogues exhibit longer half-lives and higher biological activity in vivo, significantly superior to apraglutide, and have promising clinical application prospects for the prevention and treatment of gastrointestinal diseases.
Smart Images
Figure CN122404529A_ABST